Tracy Lemonovich, MD
Infectious Disease · Cleveland, OHNPI 1366431363
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $162 of the $220 with a category attached, or 73.6%. 5 manufacturers reported payments, led by Insmed, Inc. at 39.7% of the total. That places this record below the midpoint for infectious disease clinicians in OH, where the typical reported total is $232.
Across 7 payments — averaging $31.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$87
- Astellas Pharma US Inc$58
- Viiv Healthcare Company$43
- Merck$19
- Hikma Pharmaceuticals USA$12
Across 4 payments — averaging $23,634 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$95K
What the payments were for
- Food & beverage$16274%
- Education$5826%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 1 | $87 |
| Astellas Pharma US Inc | 1 | $58 |
| Viiv Healthcare Company | 3 | $43 |
| Merck | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $12 |
How this compares
$220 in reported general payments places this provider in the 45th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 19 | $1,694 |
| CeftriaxoneCeftriaxone Sodium | 30 | $1,037 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 32 | $900 |
| Doxycycline Monohydrate | 20 | $815 |
| Cephalexin | 18 | $556 |
| Doxycycline Hyclate | 13 | $385 |
| Azithromycin | 25 | $240 |
| Omeprazole | 14 | $111 |
| Levofloxacin | 14 | $75 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Cleveland
- Melissa JenkinsCleveland$127K
- Grace McComseyCleveland$123K
- Steven GordonCleveland$78K
- Alan TaegeCleveland$76K
- Benigno RodriguezCleveland$58K
- Robin JumpCleveland$52K
- Elie SaadeCleveland$32K
- David CanadayCleveland$24K
- George YendewaCleveland$19K
- Kyle BrizendineCleveland$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.